Goldman Sachs Jacobio Pharma (1167.HK): China Healthcare Corporate Day 2026 Takeaways - Pan-KRAS Focus on 1L PDAC, Eyes on Global Phase 3 in 2027
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Goldman Sachs published post-event takeaways following Jacobio Pharma's (1167.HK) presentation at the China Healthcare Corporate Day 2026. The report centers on the company's pan-KRAS inhibitor ABSK-071, which is being developed for first-line pancreatic ductal adenocarcinoma (1L PDAC), a setting where current standard-of-care chemotherapy offers limited efficacy and significant unmet need persists.
The pan-KRAS mechanism targets multiple KRAS mutations, potentially offering broader patient applicability compared to mutation-specific inhibitors. Jacobio plans to initiate a global Phase 3 trial in 2027, though the report does not detail enrollment targets, endpoint designs, or disclosed clinical data. No new financial guidance or commercialization timelines were provided at the event.
Competitively, other pan-KRAS programs remain at early stages, positioning Jacobio among the potential first movers into late-stage development. Goldman views the Phase 3 initiation and subsequent results as critical catalysts, noting that successful outcomes could establish ABSK-071 as a blockbuster asset. Key risks include clinical failure, regulatory delays, and intensifying competition.
No specific rating, target price, or quantitative forecasts were assigned. The firm maintains coverage but awaits the 2027 Phase 3 readout for thesis validation. Jacobio's earlier-stage pipeline was not a focal point of this update.